N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment

Sponsor: Centre Hospitalier St Anne • ClinicalTrials.gov ID: NCT07741981

Registry updated: 2026-09-21
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ). Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life. A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.

Interventions

  • Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales (Biological)
    the biomarker research involves different biological sampling : blood, stool, cerebrospinal fluid, skin

Eligibility criteria

Inclusion Criteria: * Patient aged ≥ 18 years old; * Patient suffering from a psychiatric disorder according to DSM-5 criteria; * Patient with drug-resistant disease according to the definition of the protocol * Patient starting a new treatment for his pathology; * Patient informed and having signed an informed consent; * Patient covered by the social security system. Exclusion Criteria: * Patient with major neurocognitive disorder diagnosed (dementia syndrome) * Pregnant, laboring, or breastfeeding female patients * Patient deprived of liberty by judicial or administrative decision. Patient in psychiatric care under constraints may be included. * For patients accepting the lumbar punction: patients who are unable to control themselves and are likely to engage in physical or violent behavior.

Conditions

Schizophrenia Treatment Resistant Depression (TRD) Bipolar Disorder (BD) Catatonia Obsessive Compulsive Disorder (OCD)

Locations

  • GHU Paris - Psychiatrie et Neurosciences — Paris, France
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record